Lasa Supergenerics Limited, a pharmaceutical company, has announced the resignation of its Company Secretary and Compliance Officer, Mrs. Mitti Jain. The resignation is effective from the closing hours of Friday, August 29.

Revised Disclosure

The company has submitted a revised disclosure to the stock exchanges regarding this development. The initial disclosure, made on the same date, inadvertently omitted Mrs. Jain's resignation letter. Lasa Supergenerics has now rectified this oversight by providing the complete documentation, including the resignation letter, to ensure full transparency.

Reasons for Resignation

In her resignation letter, Mrs. Mitti Jain cited two primary reasons for her decision to step down:

1. The company's non-operational status
2. The absence of active business operations

Mrs. Jain stated that these factors significantly limited her ability to contribute effectively in her role as Company Secretary and Compliance Officer.

Resignation Process

The resignation was formally submitted via email on August 29. By providing the complete documentation to the stock exchanges, Lasa Supergenerics has fulfilled its regulatory obligations and ensured that all relevant information is available to stakeholders.

Implications for Lasa Supergenerics

The resignation of a key compliance officer, coupled with the reasons cited, raises questions about the current state of Lasa Supergenerics Limited. The company's non-operational status and lack of active business operations, as mentioned in Mrs. Jain's resignation letter, may be of particular interest to investors and market analysts.

As of now, Lasa Supergenerics has not announced a replacement for the position of Company Secretary and Compliance Officer. Stakeholders will likely be watching closely for further updates on the company's operational status and any potential changes in its business activities.

Lasa Supergenerics Limited, a prominent player in the pharmaceutical industry, has announced a significant expansion of its Board of Directors. The company has appointed four new Additional Directors as Non-Executive Independent Directors, each for a term of five years, effective August 05, 2025. This strategic move is aimed at enhancing the company's leadership and bringing diverse expertise to its governance structure.

New Appointments

The newly appointed directors, subject to shareholder approval, are:

1. Mr. Ketan Bhau Songal (DIN: 11228418): An expert in Agro-Veterinary Sciences, Mr. Songal brings valuable experience in livestock health, animal nutrition, and sustainable farming. His expertise includes disease management, veterinary diagnostics, and rural extension work.

2. Mr. Pravin Gadalya Lachake (DIN: 11228417): With hands-on exposure in commercial and rural poultry operations, Mr. Lachake offers practical experience in broiler and layer management, feed formulation, biosecurity, and flock health monitoring.

3. Mr. Yogesh Hari Ughada (DIN: 11230183): An enthusiastic animal care professional with over three years of practical experience, Mr. Ughada has worked alongside veterinarians and animal care teams, handling various domestic animals and livestock.

4. Mrs. Rekha Hemant Wakh (DIN: 11229667): Appointed as a Woman Director, Mrs. Wakh specializes in Animal Nutrition. Her focus is on optimizing livestock productivity through balanced feeding and scientific ration formulation.

Board Composition and Expertise

The new directors bring a wealth of experience in areas crucial to Lasa Supergenerics' business, including veterinary sciences, poultry operations, animal care, and nutrition. This diverse skill set is expected to contribute significantly to the company's strategic direction and growth.

Appointment Details

• Term: Each director is appointed for a five-year term, from August 05, 2025, to August 04, 2031.
• Independence: All four appointees are designated as Non-Executive Independent Directors.
• Disclosures: The company has confirmed that none of the new directors hold directorships in other public companies or are related to existing directors or key managerial personnel.

Corporate Governance

The appointments align with SEBI regulations, and the company has assured that none of the new directors are debarred from holding office by any SEBI order or other authority. This move underscores Lasa Supergenerics' commitment to maintaining high standards of corporate governance and bringing fresh perspectives to its board.

Looking Ahead

With these strategic appointments, Lasa Supergenerics is poised to leverage the diverse expertise of its expanded board. The company's focus on animal health and nutrition aligns well with the backgrounds of the new directors, potentially opening avenues for innovation and growth in the pharmaceutical and veterinary sectors.

The board meeting that approved these appointments was held on August 05, 2025, from 3:00 P.M. to 4:30 P.M. Shareholders will have the opportunity to approve these appointments at the upcoming General Meeting or through a Postal Ballot.